Pulmonary Arterial Hypertension News and Research

RSS

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.

Researchers identify a rare genetic change linked to neurodevelopmental disorder

Research led by Texas Children's Duncan Neurological Research Institute (Duncan NRI) and Baylor College of Medicine identified a rare genetic change that appears to cause a newly recognized neurodevelopmental disorder.

21 Sep 2026

Blocking a naturally occurring molecule reverses deadly lung disease in preclinical models

Researchers blocked a naturally occurring molecule to reverse pulmonary arterial hypertension in preclinical models, a finding that could point to a new treatment approach for people with a rare and often fatal lung disease.

2 Sep 2026

New findings highlight risks and therapeutic targets in systemic sclerosis

Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs.

7 Jun 2026

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has established a Scientific Advisory Board (SAB) focused on pulmonary hypertension (PH).

From Qureight 11 May 2026

Tiny organism offers insight into neurological side effects of chemotherapy

Chemotherapy remains one of the most powerful tools in the fight against cancer, yet it often comes with significant long-term side effects that can dramatically affect patients' quality of life.

11 Feb 2026

Sotatercept shows strong benefits for newly diagnosed pulmonary hypertension patients

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within the first year after diagnosis, according to a study published in the New England Journal of Medicine.

30 Sep 2025

Pediatric lung transplantation shows promising outcomes in China

Lung transplantation has transformed care for patients with end-stage respiratory failure, particularly among adults, where the number of procedures has grown dramatically over recent decades.

25 Sep 2025

New ESC guidelines prioritize women's autonomy in high-risk pregnancies

Updated ESC Guidelines, published today at ESC Congress 2025, put a focus on a woman's autonomy in making her own reproductive choices by promoting a transparent dialogue and shared decision-making for pregnancies that are high-risk for an adverse maternal and/or fetal event.

30 Aug 2025

Early clinical events predict disease progression in very early systemic sclerosis

The VEDOSS project has previously shown that 70% of patients with Raynaud's phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.

13 Jun 2025

New screening tool enhances early detection of pulmonary hypertension

A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows significant promise for improving the detection of pulmonary arterial hypertension (PAH)-a life-threatening form of heart failure related to high blood pressure in the lung circulation that is often overlooked due to vague symptoms such as fatigue and shortness of breath.

4 Jun 2025

New therapy shows dramatic survival benefits in advanced pulmonary arterial hypertension

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease.

29 May 2025

Promising findings for the treatment of patients with pulmonary arterial hypertension with a high risk of mortality

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, sotatercept.

16 Apr 2025

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR reduced the relative risk of major morbidity and mortality events (the composite of all-cause death, lung transplantation and PAH worsening-related hospitalization of ≥24 hours) by 76% (HR=0.24 [95% CI, 0.13-0.43]; p<0.0001 [1-sided]) compared to placebo.

1 Apr 2025

Women experience higher waiting-list mortality in lung transplantation

Research highlights gender-based disparities in lung transplantation, showing women face longer wait times yet achieve better post-transplant survival outcomes.

13 Jan 2025

Pharmacy benefit managers steer Medicare patients to use their own pharmacies

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their own pharmacies.

10 Jan 2025

Vitamin D receptor activation slows cell overgrowth in pulmonary hypertension

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in pulmonary arterial smooth muscle cells, potentially reducing disease severity in pulmonary arterial hypertension (PAH).

12 Nov 2024

New EULAR recommendations provide updated treatment strategies for systemic sclerosis

SSc is a rare connective tissue disorder, with both autoimmune and vascular features. The main hallmark is tissue and vascular fibrosis that can result in clinical heterogeneity of manifestations across the skin and internal organs.

14 Oct 2024

Protein encoded by the ASPN gene plays a protective role in pulmonary arterial hypertension

A new study from researchers with UCLA Health and collaborating organizations has found that asporin, a protein encoded by the ASPN gene, plays a protective role in pulmonary arterial hypertension (PAH).

21 Aug 2024

FDA approved PDE4 inhibitor roflumilast for atopic dermatitis

On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics' ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S. This once-daily, steroid-free cream could become a new standard of care for AD.

From Sino Biological Inc. 12 Jul 2024

Implementing patient-centered palliative care may help improve quality of life for people with heart disease

Implementing patient-centered palliative care therapies, including prescribing, adjusting or discontinuing medications as needed, may help control symptoms and improve quality of life for people with heart disease, according to "Palliative Pharmacotherapy for Cardiovascular Disease," a new scientific statement from the American Heart Association, published today in the Association's journal, Circulation: Cardiovascular Quality and Outcomes.

1 Jul 2024